C3 glomerulopathy

Contributions to Nephrology

Volumn 181, Issue , 2013, Pages 185-193

  Servais, Aude ^a,b,c   Noël, Laure Hélène ^a,b   Frémeaux Bacchi, Véronique ^d,e   Lesavre, Philippe ^a,c  

^a Department of Nephrology ^*  (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c LIPADE   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; COMPLEMENT ALTERNATIVE PATHWAY; GLOMERULONEPHRITIS; HUMAN; IMMUNOLOGY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PATHOLOGY;

COMPLEMENT C3; COMPLEMENT PATHWAY, ALTERNATIVE; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 84958675582     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000348654     Document Type: Article

References (32)

1. Walker PD, Ferrario F, Joh K, et al: Dense deposit disease is not a membranoprolifera-tive glomerulonephritis. Mod Pathol 2007; 20: 605-616. (Pubitemid 46788867)
2. Servais A, Fremeaux-Bacchi V, Lequintrec M, et al: Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44: 193-199. (Pubitemid 46580528)
3. Servais A, Noel L-H, Roumenina LT, et al: Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82:454-464.
4. Berger J, Noel L-H, Yaneva H: Complement deposition in the kidney; in Hamburger J, Crosnier J, Maxwell MH (eds): Advances in Nephrology. Chicago, Year Book Medical Publishers, 1974, vol 4, pp 37-48.
5. Sethi S, Fervenza FC, Zhang Y, et al: Prolif-erative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011; 6: 1009-1017.
6. Herlitz LC, Bomback AS, Markowitz GS, et al: Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 2012; 23:1229-1237.
7. Appel GB, Cook HT, Hageman G, et al: Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005; 16:1392-1403. (Pubitemid 41716523)
8. Sethi S, Fervenza FC, Zhang Y, et al: C3 glo-merulonephritis: clinicopathological findings, complement abnormalities, glomerular pro-teomic profile, treatment, and follow-up. Kidney Int 2012; 82:465-473.
9. Zhang Y, Meyer NC, Wang K, et al: Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 2012; 7:265-274.
10. Nasr SH, Valeri AM, Appel GB, et al: Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 2009; 4:22-32.
11. Little MA, Dupont P, Campbell E, et al: Severity of primary MPGN, rather than MPGN type, determines renal survival and posttransplantation recurrence risk. Kidney Int 2006; 69:504-511. (Pubitemid 43164442)
12. Goodship TH, Pappworth IY, Toth T, et al: Factor H autoantibodies in membranoprolif-erative glomerulonephritis. Mol Immunol 2012; 52:200-206.
13. Strobel S, Zimmering M, Papp K, et al: Antifactor B autoantibody in dense deposit disease. Mol Immunol 2010; 47:1476-1483.
14. Chen Q, Muller D, Rudolph B, et al: Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med 2011; 365:2340-2342.
15. Servais A, Noel L-H, Dragon-Durey MA, et al: Heterogeneous pattern of renal disease associated with homozygous factor H deficiency. Hum Pathol 2011; 42:1305-1311.
16. Martinez-Barricarte R, Heurich M, Valdes-Canedo F, et al: Human C3 mutation reveals a mechanism of dense deposit disease patho-genesis and provides insights into complement activation and regulation. J Clin Invest 2010; 120:3702-3712.
17. Montes T, de Jorge EG, Ramos R, et al: Genetic deficiency of complement factor H in a patient with age-related macular degeneration and membranoproliferative glomerulo-nephritis. Mol Immunol 2008; 45:2897-2904.
18. Dragon-Durey MA, Fremeaux-Bacchi V, Loi-rat C, et al: Heterozygous and homozygous factor h deficiencies associated with hemo-lytic uremic syndrome or membranoprolif-erative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004; 15:787-795. (Pubitemid 38294810)
19. Bomback AS, Smith RJ, Barile GR, et al: Ecu-lizumab for dense deposit disease and C3 glo-merulonephritis. Clin J Am Soc Nephrol 2012; 7:748-756.
20. Hogasen K, Jansen JH, Mollnes TE, et al: Hereditary porcine membranoproliferative glo-merulonephritis type II is caused by factor H deficiency. J Clin Invest 1995; 95:1054-1061.
21. Pickering MC, Cook HT, Warren J, et al: Uncontrolled C3 activation causes membranop-roliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002; 31:424-428. (Pubitemid 35154455)
22. Habbig S, Mihatsch MJ, Heinen S, et al: C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009; 75:1230-1234.
23. Schejbel L, Schmidt IM, Kirchhoff M, et al: Complement factor H deficiency and endo-capillary glomerulonephritis due to paternal isodisomy and a novel factor H mutation. Genes Immun 2011; 12:90-99.
24. Saunders RE, Abarrategui-Garrido C, Fre-meaux-Bacchi V, et al: The interactive factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and factor I mutations with structural models. Hum Mutat 2007; 28:222-234.
25. Nilsson SC, Kalchishkova N, Trouw LA, et al: Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur J Immunol 2010; 40:172-185.
26. Gale DP, de Jorge EG, Cook HT, et al: Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376:794-801.
27. Malik TH, Lavin PJ, de Jorge EG, et al: A hybrid CFHR3-1 gene causes familial C3 glo-merulopathy. J Am Soc Nephrol 2012; 23: 1122.
28. Abrera-Abeleda MA, Nishimura C, Smith JL, et al: Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with mem-branoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 2006; 43: 582-589. (Pubitemid 44048765)
29. Sethi S, Fervenza FC, Zhang Y, et al: Prolif-erative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011; 5: 1009-1017.
30. Rose KL, Paixao-Cavalcante D, Fish J, et al: Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest 2008; 118:608-618. (Pubitemid 351206550)
31. Angelo JR, Bell CS, Braun MC: Allograft failure in kidney transplant recipients with membranoproliferative glomerulonephritis. Am J Kidney Dis 2012; 57:291-299.
32. Zuber J, Fakhouri F, Roumenina LT, et al: Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8:643-657.